![]() | |
Clinical data | |
---|---|
Trade names | Lytgobi |
Other names | TAS-120 |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
License data |
|
Routes of administration | By mouth |
Drug class | Antineoplastic |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C22H22N6O3 |
Molar mass | 418.457 g·mol−1 |
3D model ( JSmol) | |
| |
|
Futibatinib, sold under the brand name Lytgobi, is an anti-cancer medication used for the treatment of cholangiocarcinoma (bile duct cancer). [1] [3] It is a kinase inhibitor. [1] [6] It is taken by mouth. [1]
Futibatinib was approved for medical use in the United States in September 2022, [1] [3] [7] [2] in Japan in June 2023 [8] [9] and in the European Union in July 2023. [4] [10]
Futibatinib is indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. [1] [3] [2] [11]
On 26 April 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Lytgobi, intended for the second-line treatment of locally advanced or metastatic cholangiocarcinoma characterized by fusion or rearrangements of fibroblast growth factor receptor (FGFR) 2. [12] The applicant for this medicinal product is Taiho Pharma Netherlands B.V. [12] Futibatinib was approved for medical use in the European Union in July 2023. [4]
Futibatinib is the international nonproprietary name (INN). [13]
![]() | |
Clinical data | |
---|---|
Trade names | Lytgobi |
Other names | TAS-120 |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
License data |
|
Routes of administration | By mouth |
Drug class | Antineoplastic |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C22H22N6O3 |
Molar mass | 418.457 g·mol−1 |
3D model ( JSmol) | |
| |
|
Futibatinib, sold under the brand name Lytgobi, is an anti-cancer medication used for the treatment of cholangiocarcinoma (bile duct cancer). [1] [3] It is a kinase inhibitor. [1] [6] It is taken by mouth. [1]
Futibatinib was approved for medical use in the United States in September 2022, [1] [3] [7] [2] in Japan in June 2023 [8] [9] and in the European Union in July 2023. [4] [10]
Futibatinib is indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. [1] [3] [2] [11]
On 26 April 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Lytgobi, intended for the second-line treatment of locally advanced or metastatic cholangiocarcinoma characterized by fusion or rearrangements of fibroblast growth factor receptor (FGFR) 2. [12] The applicant for this medicinal product is Taiho Pharma Netherlands B.V. [12] Futibatinib was approved for medical use in the European Union in July 2023. [4]
Futibatinib is the international nonproprietary name (INN). [13]